Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a Subgroup of Responders

Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not all subjects respond, and the duration of response is limited. Our aim was to determine whether two courses of teplizumab, an Fc receptor–nonbinding anti-CD3 monoclonal antibody, reduces the decline in C-peptid...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Herold, Kevan C., Gitelman, Stephen E., Ehlers, Mario R., Gottlieb, Peter A., Greenbaum, Carla J., Hagopian, William, Boyle, Karen D., Keyes-Elstein, Lynette, Aggarwal, Sudeepta, Phippard, Deborah, Sayre, Peter H., McNamara, James, Bluestone, Jeffrey A.
Format: Artigo
Langue:Inglês
Publié: American Diabetes Association 2013
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3806618/
https://ncbi.nlm.nih.gov/pubmed/23835333
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/db13-0345
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires